Clinical Trial

A Biomarker Exploration Study for Predicting Localization of Recurrence and Metastasis in Colorectal Cancer (PROBE Study)

Study acronym: PROBE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
With high incidence and mortality rate, the effective therapeutic options of colorectal cancer remain limited. Up to 50% of patients with colorectal cancer will develop metastatic disease. Recurrent lesions can be diagnosed and characterized only when tumors have reached a certain volume by present radiologic imaging techniques such as CT and MRI. The exploration of differentiated clinical applications specifically for local recurrence versus distant metastasis remains an unmet need. The aim of this study is to explore methylation, fragmentomic, and cfRNA markers associated with local recurrence and distant metastasis of colorectal cancer by multi-omics approaches. By constructing a predictive model for the localization of post-treatment recurrence and metastasis, this study will compare the accuracy of different technical approaches in predicting the localization of recurrence and metastasis after colorectal cancer treatment.
Trial Details
NCT Number NCT07685236
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Metastatic Colorectal Cancer (CRC)
Enrollment 586 participants
Start Date 2026-06-29
Primary Completion 2027-06-28 (estimated)
Study Completion 2027-06-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-06